tradingkey.logo

Prophase Labs Inc

PRPH
查看詳細走勢圖
0.615USD
-0.072-10.48%
收盤 12/24, 13:00美東報價延遲15分鐘
2.55M總市值
虧損本益比TTM

Prophase Labs Inc

0.615
-0.072-10.48%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-10.48%

5天

+485.71%

1月

+241.67%

6月

+75.71%

今年開始到現在

-18.77%

1年

-2.38%

查看詳細走勢圖

TradingKey Prophase Labs Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Prophase Labs Inc當前公司基本面數據相對謹慎,增長潛力穩定。當前估值合理,在醫療服務供應商行業排名70/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為。最高目標價16.00。中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Prophase Labs Inc評分

相關信息

行業排名
70 / 78
全市場排名
459 / 4562
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
16.000
目標均價
+5111.73%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Prophase Labs Inc亮點

亮點風險
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
業績增長期
公司處於發展階段,最新年度總收入6.77M美元
估值高估
公司最新PE估值-0.03,處於3年歷史高位
機構減倉
最新機構持股3.04M股,環比減少45.19%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉53.19K股
活躍度增加
近期活躍度增加,過去20天平均換手率4.02

Prophase Labs Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Prophase Labs Inc簡介

ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
公司代碼PRPH
公司Prophase Labs Inc
CEOKarkus (Ted William)
網址https://www.prophaselabs.com/

常見問題

Prophase Labs Inc(PRPH)的當前股價是多少?

Prophase Labs Inc(PRPH)的當前股價是 0.615。

Prophase Labs Inc 的股票代碼是什麼?

Prophase Labs Inc的股票代碼是PRPH。

Prophase Labs Inc股票的52週最高點是多少?

Prophase Labs Inc股票的52週最高點是9.349。

Prophase Labs Inc股票的52週最低點是多少?

Prophase Labs Inc股票的52週最低點是0.639。

Prophase Labs Inc的市值是多少?

Prophase Labs Inc的市值是2.55M。

Prophase Labs Inc的淨利潤是多少?

Prophase Labs Inc的淨利潤為-53.36M。

現在Prophase Labs Inc(PRPH)的股票是買入、持有還是賣出?

根據分析師評級,Prophase Labs Inc(PRPH)的總體評級為--,目標價格為16.000。

Prophase Labs Inc(PRPH)股票的每股收益(EPS TTM)是多少

Prophase Labs Inc(PRPH)股票的每股收益(EPS TTM)是-17.761。
KeyAI